Abstracts tagged "fever and treatment"

Abstract Number: 2282 • 2014 ACR/ARHP Annual Meeting
Evidence Based Recommendatinos for Diagnosis and Management of Mevalonate Kinase Deficiency (MKD)
Nienke ter Haar¹, Jerold Jeyaratnam², Jordi Anton³, Caroline Galeotti⁴, Karyl Barron⁵, Paul Brogan⁶, Luca Cantarini⁷, Marco Gattorno⁸, Gilles Grateau⁹, Veronique Hentgen¹⁰, Michael Hofer¹¹, Tilmann Kallinich¹², Isabelle Kone-Paut¹³, Jasmin Kuemmerle-Deschner¹⁴, Helen Lachmann¹⁵, Huri Ozdogan¹⁶, Seza Ozen¹⁷, Ricardo Russo¹⁸, Yosef Uziel¹⁹, Carine Wouters²⁰, Brian Feldman²¹, Bas Vastert², Nico Wulffraat²², Anna Simon²³ and Joost Frenkel², ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁴Bicêtre Hospital, University of Paris SUD, Paris, France, ⁵NIH, Bethesda, MD, ⁶Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁷University of Siena, Siena, Italy, ⁸Istituto Giannina Gaslini, Genova, Italy, ⁹Service De Médecine Interne, Hopital Tenon, Paris, France, ¹⁰Versailles Hospital, Le Chesnay Cedex, France, ¹¹Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ¹²Charite, University Medicine Berlin, Berlin, Germany, ¹³Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ¹⁴Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ¹⁵UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ¹⁶Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ¹⁷Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ¹⁸Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, ¹⁹Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ²⁰University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, ²¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²²Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²³Radboudumc, Nijmegen, Netherlands
Background/Purpose Mevalonate kinase deficiency (MKD) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking and management is mostly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].